NCT04606602View on ClinicalTrials.gov

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions
HyperlipidemiasDyslipidemiasElevated Lp(a)
Interventions
DRUG

SLN360

SLN360 for subcutaneous (s.c.) injection

DRUG

Placebo

Sodium chloride for subcutaneous (s.c.) injection

Trial Locations (8)

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research Ltd., Jacksonville

44195

Cleveland Clinic, Cleveland

45227

Metabolic and Atherosclerosis Research Center, Cincinnati

Unknown

Linear Clinical Research, Perth

Monash Medical Centre, Clayton

Amsterdam Medical Centre, Amsterdam

Hammersmith Medicines Research, London

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Silence Therapeutics plc

INDUSTRY

NCT04606602 - Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) | Biotech Hunter | Biotech Hunter